Survival Rates by Stage
Mesothelioma is staged I through IV based on how far the cancer has spread. Stage at diagnosis is the strongest single predictor of survival:
| Stage | Description | Median Survival | 5-Year Survival |
|---|---|---|---|
| Stage I | Localized to one layer of the pleura | 21–24 months | ~16% |
| Stage II | Both pleural layers involved, no lymph node spread | 18–20 months | ~10% |
| Stage III | Regional lymph node involvement or chest wall/diaphragm invasion | 15–16 months | ~5% |
| Stage IV | Distant spread to opposite lung, other organs | 12–14 months | <1% |
Note: The majority of mesothelioma patients are diagnosed at Stage III or IV because symptoms often don’t appear until disease is advanced. These figures represent historical data; immunotherapy has improved outcomes for many patients.
Impact of Cell Type on Prognosis
| Cell Type | Median Survival | Why |
|---|---|---|
| Epithelioid | 18–24 months | Slower-growing, responds better to chemotherapy and immunotherapy |
| Biphasic | 12–18 months | Mixed behavior; prognosis depends on ratio of cell types |
| Sarcomatoid | 6–12 months | Most aggressive, treatment-resistant, rapid progression |
How Immunotherapy Has Changed Prognosis
In 2020, the FDA approved nivolumab (Opdivo) plus ipilimumab (Yervoy) as a first-line treatment for unresectable pleural mesothelioma — the first new mesothelioma treatment approved in 16 years. The CheckMate 743 trial showed:
- Median overall survival of 18.1 months with immunotherapy vs. 14.1 months for chemotherapy alone
- 2-year survival rate of 41% vs. 27% for chemotherapy
- Particularly strong benefit for non-epithelioid (sarcomatoid and biphasic) cell types, which respond poorly to chemotherapy
Additionally, pembrolizumab (Keytruda) has shown activity in mesothelioma clinical trials. The combination of immunotherapy with chemotherapy and surgery continues to be studied at major cancer centers.
Factors That Improve Prognosis
- Earlier stage at diagnosis — the single most important factor
- Epithelioid cell type — more treatment-responsive
- Peritoneal location — best outcomes with HIPEC surgery
- Good performance status — patients in good overall health tolerate more aggressive treatment
- Treatment at a mesothelioma specialty center — patients treated by high-volume specialists have better outcomes
- Younger age at diagnosis
- Female sex — women have modestly better survival in most studies
Peritoneal Mesothelioma: The Outlier
Peritoneal mesothelioma treated with cytoreductive surgery and HIPEC (heated intraperitoneal chemotherapy) has dramatically better survival outcomes than pleural mesothelioma. Studies from major centers report:
- Median survival of 40–92 months for patients who undergo complete cytoreduction
- 5-year survival rates of 40–50% in specialized center series
- Some patients achieving long-term disease-free survival beyond 10 years
Not all peritoneal mesothelioma patients are candidates for HIPEC surgery. Eligibility requires adequate health status, limited disease spread, and evaluation by a surgeon experienced in this procedure. Major HIPEC centers in the U.S. include MD Anderson, Mayo Clinic, and several National Cancer Institute-designated centers.